Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Do atherosclerotic events change lipid lowering therapy use in clinical practice? The answer with RWE
Session:
Posters (Sessão 4 - Écran 5) - Risco Cardiovascular 2
Speaker:
Daniel Seabra De Carvalho
Congress:
CPC 2022
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.2 Risk Factors and Prevention – Cardiovascular Risk Assessment
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
Daniel Seabra; Cristina Gavina; Francisco Araújo; Marta Afonso-Silva; Diana Grangeia; Tiago Taveira-Gomes
Abstract
<p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Introduction</strong></span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000">Acute atherosclerotic cardiovascular events (ASCV) significantly increase risk of its recurrence and should prompt lipid lowering therapy (LLT) intensification towards more ambitious targets. This study aims to analyze LLT changes after an ASCV and respective LDL-C control.</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Methods</strong></span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000">Retrospective population-based study from a region of Northern Portugal. Population was composed of patients with ≥1 General Practice appointment in the three years prior to the index date. We created incident cohorts for Myocardial Infarction (MI), Peripheral Artery Disease (PAD), Ischemic stroke (IS), Recurrent ASCV (2+ events at most 2 years apart). We performed descriptive analysis of the cohorts at baseline (pre-event) and reported LDL-C control and LLT switches at discharge time (post-event) and at 1-year follow-up.</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Results</strong></span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000">Moderate intensity statins monotherapy is the most used LLT before and after ASCV. After ASCV hospitalization, LLT is upscaled in 19.1% of MI patients, in 9.9% of PAD, in 9.8% of IS and in 11.0% of recurrent events patients. LDL-C mean absolute value 1-year after the ASCV is 100 mg/dl, 105 mg/dl, 107 mg/dl and 102 mg/dl for patients with MI, PAD, IS, and recurrent events, respectively. LDL-C target values are achieved in <5% of the patients (Table1).</span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000"><strong>Conclusion</strong></span></span></span></p> <p><span style="font-size:11pt"><span style="font-family:Arial"><span style="color:#000000">These real-world data show that LLT is not adequately adjusted for goals after an acute cardiovascular event, which may explain the low rate of patients with LDL-C at the therapeutic target recommended in the Guidelines. There is a need to optimize LLT in clinical practice in order to reduce ASCV and mortality.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site